Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-03-25
2000-06-27
Brusca, John S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435375, 536 245, A61K 3170, C07H 2100
Patent
active
06080727&
ABSTRACT:
The invention generally provides for compositions and methods of inhibiting the proliferation of human melanoma cancer cells. By administering a therapeutically effective amount of a c-myc oligonucleotide to a human melanoma cancer cell, melanoma cancer cell proliferation can be arrested or inhibited, metastases reduced from a tumor, and apoptosis induced in melanoma cancer cells. Oligonucleotides that are complementary to c-myc polynucleotides are referred to herein as "c-myc oligonucleotides." A particularly efficacious embodiment of the invention relates to compositions and methods concerning the co-administration of c-myc oligonucleotides and cisplatin.
REFERENCES:
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4725677 (1988-02-01), Koster et al.
patent: 4757055 (1988-07-01), Miller et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4973679 (1990-11-01), Caruthers et al.
patent: 4980460 (1990-12-01), Moloko et al.
patent: 5130302 (1992-07-01), Speilvogel et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5166387 (1992-11-01), Hirschbein
patent: 5183885 (1993-02-01), Bergot
patent: 5585479 (1996-12-01), Hoke et al.
Ahern et al. Overexpression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines, is associated with metastatic potential in nude mice. Anticancer Res. 13: 1365-1372, 1993.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93, 3161-3163, Apr. 1996.
Osanto et al. Downmodulation of c-myc expression by interferon and tumour necrosis factor precedes growth arrest in human melanoma cells. Eur. J. Cancer, 28A: 1622-1627, 1992.
Zon et al. "Phosphorothioate oligonucleotides" in Oligonucleotides and Analogues, Eckstein, ed. IRL Press, New York, pp. 87-108, 1991.
Leonetti, et al., "Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice", J. Nat. Cancer Institute, 88(7):421-429 (Apr. 3, 1996).
Agrawal et al., Proc. Natl. Acad. Sci. USA, vol. 88:7595-7599 (1991).
Arad et al., Biochem. Biophy. Acta., vol. 859: 88-94 (1986).
Battey et al., Cell, vol. 34:779-787 (1993).
Beal and Dervan, J. Am. Chem. Soc., vol. 114:4976-4982 (1982).
Beal and Dervan, Nucleic Acids Research, vol. 20:2773-2776 (1992).
Beacage and Iyer, Tetrahedron, vol. 48:2223-2311 (1992).
Branda et al., Biochem. Phramacol., vol. 45:2037-2043 (1993).
Biro S., et al., "Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration," Proc. Natl. Sci., vol. 90:654-658 (1993).
Blume et al., Nucleic Acids Research, vol. 20:1777-1784 (1992).
Chenevix-Trench et al., Oncogene, vol. 5:1887-1193 (1990).
Cheng et al., J. Am. Chem. Soc., vol. 114:4465-4474 (1992).
Chomczsky et al., Anal. Biochem., vol. 162:156-159 (1987).
Citro et al., Proc. Natl. Acad. Sci. USA, vol. 89:7031-7035 (1992).
Crooke, Ann. Rev. Pharmacol. Toxicol., vol. 32:329-376 (1992).
Dagle et al., Antisense Rev. Dev., vol. 1:11-20 (1991).
Distefano et al., Proc. Natl. Acad. Sci. USA., vol. 90:1179-1183 (1993).
Dugaiaczyk et al., Biochemistry, vol. 22:1605-1613 (1983).
Elsas, A.V., et al., "ras Oncogene Activation Does Not Induce Sensitivity to Natural Killer Cell-Mediated Lysis in Human Melanoma, "The Journal of Investigative Dermatology, vol. 103, No. 5:117S-121S (1994).
Evan et al., Mol. Cell Biol., vol. 5:3610-3616 (1985).
Finberg et al., Anal. Biochem., vol. 132:6.
Froehler et al., Tetrahedron Lett., vol. 33:5307-5310 (1992).
Gazin et al., E.M.B.O. Journal., vol. 32:383-387 (1984).
Geran et al., Cancer Chemother. Rep., vol. 3:1-88 (1972).
Giovannangeli et al., Proc. Natl. Acad. Sci. USA, vol. 89:8631-8635 (1992).
Greco et al., Anticancer Res., vol. 7:839-844 (1987).
Greco et al., Tumori, vol. 65:169-180 (1979).
Hijiya et al., Proc. Natl. Acad. Sci. USA, vol. 91:4499-4503 (1994).
Lurquin "Incorporation of Drugs, Proteins and Genetic Material," Liposome Technology, vol. II, Gregoriadis, ed. (CRC press), pp. 187-221 (1984).
Krieg et al., Nature, vol. 374:546-549 (1995).
Lemaiture et al., Proc. Natl. Acal. Sci. USA, vol. 84:648-652 (1987).
Lesinkowski, Bioinorganic Chemistry, vol. 21:127-155 (1993).
Letsinger et al., Proc. Natl. Acad. Sci., vol. 86:6553-6556 (1989).
Lombardi et al., Cell, vol. 49:161-170 (1987).
Marcu et al., Ann. Rev. Biochem., vol. 61:809-860 (1992).
Marshall et al., Science, vol. 259:1564-1570 (1993).
McShan et al., J. Biol. Chem., vol. 267:5712-5721 (1992).
Mergny et al., Biochemistry, vol. 30:9791-9798 (1991).
Milligan et al., J. Med. Chem., vol. 36:1923-1937 (1993).
Mitzutani, Y., et al., "Enhanced Susceptibility to c-myc Antisense Oligonucleotide-Treated Human Renal Cell Carcinoma Cells to Lysis by Peripheral Blood Lymphocytes," J. of Immunotherapy, vol. 17:78-87 (1995).
Mitzutani, Y., et al., "Enhancement of Sensitivity of Urinary Bladder Tumor Cells to Cisplatin by Cisplatin by c-myc Antisense Oligonucleotide," Cancer, vol. 74, No. 9:2546-2554 (1994).
Mojcik et al., Clin. Immunol. Immunopathol., vol. 67:130-136 (1993).
Moser and Dervan, Science, vol. 238:645-650 (1987).
Mottolese et al., Melanoma Res., vol. 4:53-58 (1994).
Neiborrow-Skorska, M., et al, "Oncogene-targeted antisense olgodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment," Folia Histochemica, vol. 32, No. 1:35-40 (1994).
Neilsen et al., Anti-cancer Drug Design, vol. 8:53-63, 1993 (International application PCT/EP92/01220).
Normanno, N., Bianco, C., et al., "Growth Inhibition of Human Colon Carcinoma Cells By Combinations of Anti-Epidermal Growth Factor-related Growth Factor Antisense Olgonucleotides," Clinical Cancer Research, vol. 2:601-609 (1996).
Peltenburg, L.T.C., Schrier, P.I., "Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements," Immunogenetics, vol. 40:54-61 (1994).
Roberts et al., Proc. Natl. Acad. Sci. USA., vol. 88:9397-9401 (1991).
Roberts et al., Science, vol. 258:1463-1466 (1992).
Shea et al., Nucleic Acids Research, vol. 18:3777-3783 (1990).
Stein, C.A., "Antitumor Effects of Antisense Phosphorothiolate c-myc Oligodeoxynucleotides: a Question of Mechanism," J. Natl. Cancer Inst., vol. 88:391-393 (1996).
Stein et al., Nucleic Acid Res., vol. 16:3209-3221 (1988).
Szostak et al., Meth. Enzymol., vol. 68:419-429 (1979).
Ulmann et al., Chemical Reviews, vol. 90:543-584 (1990).
Versteeg, P., "C-myc down-regulates class 1 HLA expression in human melanomas," The EMBO Journal, vol. 7, No. 4:1023-1029 (1988).
Wagner et al., Proc. Natl. Acad. Sci. USA, vol. 87:3410-3414 (1990).
Walker, T.L., "Tumor cells surviving in vivo cisplatin chemotherapy dislpay elevated cmyc expression," 610-614 (1995).
Watt et al., Nature, vol. 303:725-728 (1983).
Whartenby, K.A., et al., "Biology of Disease," Laboratory Investigation, vol. 72, No. 2:131-145 (1995).
Wickstrom et al., J. Biochem. Biophys. Methods, vol. 13:97-102 (1987).
Yaswen et al., Antisense Res. Dev., vol. 3:67-77 (1993).
Yoon et al., Proc. Natl. Acad. Sci., vol. 75:280-284 (1974).
Zamecnik and Stephenson, Proc. Natl. Acad. Sci., vol. 75:280-284 (1974).
Zon and Geiser, Anti-Cancer Drug Design, vol. 6:539-568 (1991).
Zupi et al., Proc. Am. Assoc. Cancer Res., vol. 26:22 (1985).
Brusca John S.
Istituto Regina Elena
Larson Thomas G.
LandOfFree
Oligonucleotide treatments and compositions for human melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide treatments and compositions for human melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide treatments and compositions for human melanoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784851